P2 Receptor
信号通路图
研究领域
抑制剂选择性比较
P2 Receptor产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S2855 |
MRS 2578MRS 2578是一种有效的P2Y6受体抑制剂，IC50为37 nM，对P2Y1， P2Y2， P2Y4和P2Y11受体的作用活性很弱。 |
||
| S1984 |
Ticlopidine HClTiclopidine HCl是一种P2受体抑制剂，可以抑制ADP诱导的血小板聚集，IC50约为2μM. |
||
| S4637 |
Prasugrel HydrochloridePrasugrel hydrochloride是一种哌嗪衍生物，是血小板聚集抑制剂，在急性冠脉综合征患者中阻止血栓形成。 |
||
| S3737 |
Cangrelor TetrasodiumCangrelor是一种有效的、竞争性的P2Y12 receptor抑制剂，可通过静脉注射、抑制ADP诱导的血小板凝集。 |
||
| S1258 |
PrasugrelPrasugrel是一种噻吩吡啶类的ADP receptor (P2Y12) 拮抗剂，用于降低血栓相关的心血管紊乱。 |
||
| S4079 |
TicagrelorTicagrelor是第一个口服的可以可逆结合的P2Y12受体拮抗剂。 |
Effect of antiplatelet drugs on platelet aggregation in healthy individuals. Samples from healthy individuals were preincubated with anti-platelet drugs (n = 3). Curves and columns show mean platelet aggregation and the relationship between platelet aggregation and drug concen-tration. Bars represent standard deviations. *P < 0.05 as compared with platelet aggregation with the same agonist but no drugs added; pairedStudent’s t-test. (A-C) The drugs tested were abciximab (A), ticagrelor (B), and vorapaxar (C).
|
|
| S8725New |
A-804598A-804598是一种选择性的P2X7R拮抗剂。它对大鼠P2X7受体（IC50 = 10 nM）、小鼠P2X7受体（IC50 = 9 nM）和人源P2X7受体（IC50 = 11 nM）皆具有高亲和力。 |
||
| S8519 |
A-317491A-317491是一种新型的、有效的、选择性的P2X3和P2X2/3受体的非核苷类拮抗剂，对人源P2X3和P2X2/3的Ki值分别为22 nM和9 nM。 |
||
| S7705 |
A-438079 HClA-438079 HCl 是一种有效的选择性 P2X7 receptor 拮抗剂，pIC50 为 6.9。 |
||
| S1415 |
ClopidogrelClopidogrel是一种口服的，噻吩吡啶类抗血小板药物。 |
(A) HPLC glycan traces of IgG recovered from joint after K/BxN and PBS or B4ST6Fc treatment with or without clopidogrel. (B) Ratios of monosialylated and agalactosylated glycans (S1/G0) from IgG described in (A). |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S2855 |
MRS 2578MRS 2578是一种有效的P2Y6受体抑制剂，IC50为37 nM，对P2Y1， P2Y2， P2Y4和P2Y11受体的作用活性很弱。 |
||
| S1984 |
Ticlopidine HClTiclopidine HCl是一种P2受体抑制剂，可以抑制ADP诱导的血小板聚集，IC50约为2μM. |
||
| S4637 |
Prasugrel HydrochloridePrasugrel hydrochloride是一种哌嗪衍生物，是血小板聚集抑制剂，在急性冠脉综合征患者中阻止血栓形成。 |
||
| S3737 |
Cangrelor TetrasodiumCangrelor是一种有效的、竞争性的P2Y12 receptor抑制剂，可通过静脉注射、抑制ADP诱导的血小板凝集。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1258 |
PrasugrelPrasugrel是一种噻吩吡啶类的ADP receptor (P2Y12) 拮抗剂，用于降低血栓相关的心血管紊乱。 |
2017, 42(6):755-761 |
|
| S4079 |
TicagrelorTicagrelor是第一个口服的可以可逆结合的P2Y12受体拮抗剂。 |
2018, 10.1111/jth.14318 2017, 15(6):1191-1202 2015, 10.1016/j.jpba.2015.06.009 |
Effect of antiplatelet drugs on platelet aggregation in healthy individuals. Samples from healthy individuals were preincubated with anti-platelet drugs (n = 3). Curves and columns show mean platelet aggregation and the relationship between platelet aggregation and drug concen-tration. Bars represent standard deviations. *P < 0.05 as compared with platelet aggregation with the same agonist but no drugs added; pairedStudent’s t-test. (A-C) The drugs tested were abciximab (A), ticagrelor (B), and vorapaxar (C).
|
| S8725New |
A-804598A-804598是一种选择性的P2X7R拮抗剂。它对大鼠P2X7受体（IC50 = 10 nM）、小鼠P2X7受体（IC50 = 9 nM）和人源P2X7受体（IC50 = 11 nM）皆具有高亲和力。 |
||
| S8519 |
A-317491A-317491是一种新型的、有效的、选择性的P2X3和P2X2/3受体的非核苷类拮抗剂，对人源P2X3和P2X2/3的Ki值分别为22 nM和9 nM。 |
||
| S7705 |
A-438079 HClA-438079 HCl 是一种有效的选择性 P2X7 receptor 拮抗剂，pIC50 为 6.9。 |
2018, 1864(9 Pt B):2890-2900 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1415 |
ClopidogrelClopidogrel是一种口服的，噻吩吡啶类抗血小板药物。 |
2017, S0092-8674(17)31431-9 2018, 57(12):1690-1697 |
(A) HPLC glycan traces of IgG recovered from joint after K/BxN and PBS or B4ST6Fc treatment with or without clopidogrel. (B) Ratios of monosialylated and agalactosylated glycans (S1/G0) from IgG described in (A). |
